ArticleThe world journal of men's health2026
Efficacy and Safety of Ginseng Berry Extract (SIRTBERRY™) in Treating Andropause Symptoms: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aimed to evaluate the efficacy and safety of ginseng berry extract (GBE) (SIRTBERRY™) in treating andropause symptoms in aging men. MATERIALS AND
methodsIn this randomized, double-blind, placebo-controlled trial, 116 men with andropause symptoms were assigned to receive either 700 mg/day GBE or placebo for 8 weeks. The primary efficacy variables included changes in the aging male symptoms (AMS) scale and improvement rate as per the androgen deficiency in aging male (ADAM) questionnaire, from the baseline. Secondary efficacy measurements included changes in the total and free testosterone levels, serum lipid levels, International Index of Erectile Function (IIEF) scores, International Prostate Symptom Score (IPSS), and various hormonal and metabolic markers.
resultsThe GBE group exhibited significant improvements in AMS scores, ADAM improvement rates, and IIEF scores compared to the placebo group. Specifically, the GBE group showed a 70% improvement in ADAM scores versus a 47.83% improvement in the placebo group (p=0.0376), and a greater reduction in AMS scores (p=0.0205). Significant enhancements were observed in erectile function, with the IIEF scores improved more in the GBE group (p=0.0334), particularly in the erectile function domain (p=0.0290). No serious adverse event was reported, and the safety profile of GBE was found to be comparable to that of placebo.
conclusionsGBE significantly improved andropause symptoms, including sexual function, and demonstrated a favorable safety profile, suggesting its potential as a safe and effective alternative treatment for testosterone deficiency syndrome. Further research regarding its long-term benefits and applicability to broader populations is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.